Reliva received approximately US$40 million of Aurora common shares.
Aurora Cannabis Inc. (NYSE: ACB), the Canadian company defining the future of cannabinoids worldwide, today announced it has completed the previously announced acquisition of Reliva LLC, a leader in the sale of hemp-derived CBD products in the United States for approximately US$40 million of Aurora common shares. The transaction also includes a potential earn-out of up to a maximum of US$45 million payable at Aurora's option in shares or cash contingent upon Reliva achieving certain financial targets over the next two years.
We believe this partnership provides the opportunity for significant growth in the United States and internationally, and we're excited to get to work.Miguel Martin, CEO of Reliva
"We are pleased to have closed the Reliva transaction ahead of schedule. The partnership between Aurora and Reliva is expected to create a market-leading international cannabinoid platform that we believe can deliver robust revenue and profitable growth," said Michael Singer, Executive Chairman and Interim CEO of Aurora. "I would like to officially welcome Miguel Martin and his team to Aurora, and look forward to increasing Aurora's operating scale, international reach, and product and brand diversity while in parallel, we remain focused on delivering Adjusted EBITDA profitability in Canada for the benefit of all shareholders."
Miguel Martin, CEO of Reliva commented, "We are delighted to join the Aurora team. "
To learn more about Aurora Cannabis, visit the company HQ here.
Disclaimer: Past performance is not an indicator of future performance.
& Keep Up to Date
Get the latest pot stock recommendations, cannabis news
and industry updates straight to your inbox!